Supernus Pharmaceuticals Inc (NASDAQ: SUPN) is 23.01% higher on its value in year-to-date trading and has touched a low of $25.53 and a high of $39.37 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SUPN stock was last observed hovering at around $35.59 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $35.60, the stock is -2.27% and -0.22% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.13 million and changing 0.03% at the moment leaves the stock 11.75% off its SMA200. SUPN registered 21.79% gain for a year compared to 6-month gain of 33.23%. The firm has a 50-day simple moving average (SMA 50) of $35.6266 and a 200-day simple moving average (SMA200) of $31.8409.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -1.71% loss in the last 1 month and extending the period to 3 months gives it a 18.90%, and is -1.71% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.46% over the week and 2.97% over the month.
Supernus Pharmaceuticals Inc (SUPN) has around 652 employees, a market worth around $1.97B and $651.97M in sales. Current P/E ratio is 33.33 and Fwd P/E is 18.80. Profit margin for the company is 9.16%. Distance from 52-week low is 39.44% and -9.58% from its 52-week high. The company has generated returns on investments over the last 12 months (5.76%).
with sales reaching $154.51M over the same period.The EPS is expected to grow by 21.50% this year, but quarterly earnings will post 5.70% year-over-year. Quarterly sales are estimated to shrink -5.96% in year-over-year returns.
Supernus Pharmaceuticals Inc (SUPN) Top Institutional Holders
379.0 institutions hold shares in Supernus Pharmaceuticals Inc (SUPN), with institutional investors hold 119.28% of the company’s shares. The shares outstanding are 55.22M, and float is at 52.88M with Short Float at 12.55%. Institutions hold 113.30% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 10.39 million shares valued at $278.0 million. The investor’s holdings represent 18.903% of the SUPN Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 6.14 million shares valued at $164.18 million to account for 11.1635 of the shares outstanding. The other top investors are ARMISTICE CAPITAL, LLC which holds 5.27 million shares representing 9.5892% and valued at over $141.03 million, while DIMENSIONAL FUND ADVISORS LP holds 5.2145 of the shares totaling 2.87 million with a market value of $76.69 million.
Supernus Pharmaceuticals Inc (SUPN) Insider Activity
The most recent transaction is an insider sale by Bhatt Padmanabh P., the company’s Sr. VP of IP, CSO. SEC filings show that Bhatt Padmanabh P. sold 21,495 shares of the company’s common stock on Dec 03 ’24 at a price of $36.68 per share for a total of $0.79 million. Following the sale, the insider now owns 9679.0 shares.
Still, SEC filings show that on Nov 11 ’24, NEWHALL CHARLES W III (Director) disposed off 10,700 shares at an average price of $36.24 for $0.39 million. The insider now directly holds 130,275 shares of Supernus Pharmaceuticals Inc (SUPN).
